Abstract 324P
Background
Small cell lung cancer (SCLC) is a highly aggressive tumor that represents 15% of lung tumors. It is characterized by a high initial response rate to platinum-etoposide (PE) - based chemotherapy, but also by rapid resistance to it.We analyzed whether administration of the fulldose PE regimen compared with a reduced dose intensity (DI) in patients with extensive stage SCLC (ES-SCLC) results in better overall survival (OS) stratified by performance status (PS).
Methods
This is an observational, analytical, retrospective study in which we analyzed the data of 76 patients with ES-SCLC who received treatment with PE as first line between January 2016 and March 2022. The baseline characteristics of the patients, the treatments received and the toxicities derived from them were collected. The main response variable analyzed has been the OS based on the ID received (defined as mg/m2/week and stratified into three percentage ranges for analysis: 0–49, 50–74 and 75–100 based on the number of PE cycles received and the percentage of dose with which each drug has been administered). The data have been processed with IBM ®-SPSS® Statistics v. 29. The information has been collected from Diraya Estación Clínica® v 4.0.80 and Farmis-Oncofarm®.
Results
We collected data from 76 patients with ES-SCLC (62 men), with a median age of 67 years. We grouped patients according to their PS: PS ≤1 (68.4%) and PS ≥2 (31.6%) and previously described DI percentage ranges. We compared OS based on DI stratified by baseline status using Kaplan-Meier survival analysis. In patients with PS ≤1, the median OS (mOS) for the three DI percentage ranges (0–49, 50–74, and 75–100) was 1, 6 (95%CI=3.7–8.3), and 10 (95%CI=8.2–11.8) months, respectively (Log Rank p < 0.001). In PS ≥2, the mOS for the three ID percentage ranges was 1, 7 (95%CI=5.1–8.8) and 11 (95%CI=7.5–14.5) months, respectively (Log Rank p < 0.001). The main toxicity was hematologic. No patient died due to treatment-related toxicity.
Conclusions
Patients with ES-SCLC benefit from receiving full-doses of PE in terms of overall survival, with the differences found being statistically significant.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E.M. Fernandez: Financial Interests, Institutional, Other, Clinical trial sub-investigator: BeiGene, MSD, Roche – Genentech, Daiichi Sankyo, AstraZeneca, Gilead Sciences; Other, Personal, Other, Travel and Accommodations: Pfizer, Merck Serono, Sanofi, Novartis. J. Fuentes Pradera: Financial Interests, Institutional, Other: BeiGene, MSD, Roche, Daiichi Sankyo, AstraZeneca, Gilead; Financial Interests, Personal, Advisory Role: MSD, Roche; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Takeda, AstraZeneca, Pfizer, Sanofi. I. Beltrán: Financial Interests, Institutional, Other, Clinical Trial Sub-Investigator: BeiGene, MSD; Financial Interests, Institutional, Other, Clinical trial subinvestigator: Merck sharp & Dohme, Roche, Daiichi Sankyo, Gilead Sciences; Other, Personal, Other, Travel and accommodation: Merck, Servier, Eisai. A. Sanchez Vegas: Financial Interests, Institutional, Other: BeiGene, MSD, Roche, Daiichi Sankyo, AstraZeneca, Gilead; Other, Personal, Invited Speaker: Pfizer. M. Chaves-Conde: Financial Interests, Institutional, Other: BeiGene, MSD, Roche, Daiichi Sankyo, AstraZeneca, Gilead; Other, Personal, Invited Speaker: MSD, Merck, Bristol Myers Squibb.